Novo Nordisk India, the market leader in diabetes care has introduced two insulin analogues NovoMix 30 and NovoRapid. NovoMix 30 is premixed analogue and NovoRapid is rapid-acting analogue. NovoMix 30 and NovoRapid are available in the world's most preferred insulin delivery device - FlexPen, it is the first company to introduce two insulin analogues.

Insulin analogues are one of the major advances in insulin therapy in recent times. They are genetically engineered products in which human insulin molecules are modified so as to enable safer and simpler insulin regimens.

NovoMix 30 and NovoRapid are the result of a 20 year research program from Novo Nordisk. We believe with the launch of NovoMix 30 and NovoRapid more benefit of the insulin therapy can be given to more patients, hopefully reducing the terrible complications associated with diabetes.

Now with the availability of NovoMix 30 and NovoRapid the above problems of hypoglycemia, fear of injection and poor therapy compliance is reduced.

Unlike conventional insulin, NovoMix 30 and NovoRapid can be injected just before or after the meal making compliance easy. Traditional insulin needed to be taken 30 minutes before meals. Unfortunately if the meals got delayed this would lead to hypoglycemia.

Launching NovoMix30 and NovoRapid, Sanjeev Shishoo, managing director, Novo Nordisk India Pvt. Ltd., said "Novo Nordisk India is committed to providing the best and the most advanced therapy for people with diabetes in India. Analogues will change the face of diabetes care with safe and simple insulin regime, while facilitating early insulin initiation."

Novo Nordisk India has always been the pioneer in advanced diabetes care therapies. It was the first company to bring in Porcine, Human insulin's and the pen delivery devices.

Shishoo added, "The three chief advantages of insulin analogues NovoMix30 and NovoRapid are, it offers greater flexibility, higher efficacy and enhanced safety in the insulin regime."

With NovoMix30 and NovoRapid the physician and the patient can now aim for lower blood glucose control targets with the 'fear/risk of hypoglycemia (low blood sugar)' being overcome. Currently, hypoglycemia, other than convenience and fear of injection, is one of the major limiting factors a major barrier for insulin initiation.